Binds Receptor Patents (Class 424/143.1)
  • Patent number: 11553877
    Abstract: A CPU of a health management apparatus functions as an acquisition unit, a first derivation unit, and a screen output control unit. The acquisition unit acquires a body-fat percentage which is an obesity parameter indicating the degree of obesity of a target pet and bone density which is a bone parameter indicating the degree of bone strength of the target pet. The first derivation unit derives health conditions of the target pet on the basis of a correlation between the body-fat percentage and the bone density. A screen output control unit performs control to output a medical examination result display screen on which the health conditions are displayed.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: January 17, 2023
    Assignee: FUJIFILM CORPORATION
    Inventor: Yasuhisa Kaneko
  • Patent number: 11518815
    Abstract: The application provides anti-ROR1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: December 6, 2022
    Assignees: SYSTIMMUNE, INC., BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.
    Inventors: Ole Olsen, Phil Tan, Dong Xia, David Jellyman, Brian Kovacevich, Bill Brady, Blair Renshaw, Zeren Gao, Yi Zhu
  • Patent number: 11498968
    Abstract: The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: November 15, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Cannarile, Anna-Maria Jegg, Francesca Michielin, Carola Ries, Dominik Ruettinger, Martin Weisser
  • Patent number: 11498969
    Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: November 15, 2022
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Lydie Baret-Cormel, Tanya Momtahen, Stefano Fiore, Janet Van Adelsberg
  • Patent number: 11492411
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: November 8, 2022
    Assignee: Amgen Fremont Inc.
    Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
  • Patent number: 11473150
    Abstract: The present invention relates to methods for detecting, diagnosing, prognosing, monitoring, and treating a patient with hepatocellular carcinoma. In particular, the invention provides diagnostic markers for the detection and treatment of patients who would benefit from immunotherapy, i.e., patient who would be most responsive to immunotherapy.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 18, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Daniela Sia, Josep Maria Llovet I Bayer, Augusto Villanueva-Rodriguez
  • Patent number: 11421034
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 23, 2022
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Patent number: 11419318
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: August 23, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Yajun Tang, Jeffrey D. Lee, Min Gao, Susan D. Croll, Lynn Macdonald, Ying Hu, Carmelo Romano
  • Patent number: 11384142
    Abstract: This invention concerns methods of treating a patient diagnosed with a platinum-resistant ovarian cancer comprising administering to said patient an effective amount of an anti-VEGF antibody and a chemotherapeutic.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 12, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Bollag, Corrado Bernasconi
  • Patent number: 11351229
    Abstract: The present invention provides methods of treating infantile spasms in a subject in need thereof. In certain embodiments, the method comprises administering to the subject both vigabatrin (VGB) and insulin-like growth factor 1 (IGF-1), a biologically active fragment thereof, or any derivative thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: June 7, 2022
    Assignee: Baylor College of Medicine
    Inventors: John W. Swann, Chong L. Lee, John T. Le, James D. Frost, Jr.
  • Patent number: 11291722
    Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 5, 2022
    Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIVERSITY
    Inventors: Hyung Joo Kwon, Yong Sung Kim
  • Patent number: 11286301
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 29, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gerlinde Wernig, Irving L. Weissman
  • Patent number: 11274281
    Abstract: The invention provides methods, compositions, uses and kits relating to exosomes isolated from progenitor cells.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: March 15, 2022
    Assignee: ReCyte Therapeutics, Inc.
    Inventors: Dana Larocca, Mohammad Hassanipour, Paola A. Bignone
  • Patent number: 11248048
    Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: February 15, 2022
    Assignee: Y-BIOLOGICS INC.
    Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chui Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
  • Patent number: 11220544
    Abstract: The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or antigen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (“ICD”) of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypeptide is useful in a method of detecting or treating a condition or disease.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 11, 2022
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Luc Roland Desnoyers, Amy Grace DuPage
  • Patent number: 11123426
    Abstract: Methods for alleviating the suppression of humoral immunity by myeloid-dependent suppressor cells (MDSCs) are provided which include the administration of a VISTA antagonist and an iNOS/NO inhibitor in a subject in need thereof, e.g., subjects with cancer or infectious disease wherein VISTA is aberrantly expressed. This combination has been discovered to elicit a synergistic or additive effect on alleviating suppression of humoral immunity by VISTA which is elicited by MDSCs.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 21, 2021
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Kathy A. Green, Li Wang, Randolph J. Noelle, William R. Green
  • Patent number: 11124575
    Abstract: An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: September 21, 2021
    Assignees: University of Saskatchewan, The Governing Council of the University of Toronto
    Inventors: Sachdev Sidhu, Shane Miersch, Clarence Ronald Geyer
  • Patent number: 11118168
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 14, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11098109
    Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Daniel A. Vallera
  • Patent number: 11098098
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 24, 2021
    Assignee: CureLab Oncology, Inc.
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Patent number: 11096962
    Abstract: The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 24, 2021
    Assignee: NANOBIOTIX
    Inventors: Julie Marill, Agnes Pottier, Laurent Levy
  • Patent number: 11066442
    Abstract: Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: July 20, 2021
    Assignee: ENB Therapeutics, Inc.
    Inventor: Sumayah Jamal
  • Patent number: 11041212
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 22, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Angela H. Ting, Byron H. Lee
  • Patent number: 11034940
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 15, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11028182
    Abstract: Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 8, 2021
    Assignee: Zymeworks Inc.
    Inventors: Eric Escobar-Cabrera, Leonard G. Presta
  • Patent number: 11028176
    Abstract: The present disclosure provides, inter alia, anti-peripheral lymph node addressin antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: June 8, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Reza Abdi
  • Patent number: 11008620
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 18, 2021
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • Patent number: 10995152
    Abstract: Polypeptide compositions comprising a human immunoglobulin constant region with a modified IgG4 hinge region having an N-terminal deletion of 1, 2, 3, 4, 5 amino acids, relative to a native human IgG4 hinge sequence are provided. In some embodiments the hinge sequence further comprises the amino acid substitution S228P (Eu numbering). Polypeptides comprising the modified sequence optionally comprise a binding moiety specific for an epitope that is present on red blood cells; and can provide for reduced agglutination of hematopoietic cells compared to a comparable polypeptide with a native hinge region.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 4, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Patent number: 10982000
    Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 20, 2021
    Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
  • Patent number: 10982001
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: April 20, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
  • Patent number: 10975153
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: April 13, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
  • Patent number: 10973896
    Abstract: The present invention relates to a method of treating or preventing melanoma using vaccination or immunisation, wherein said vaccination or immunisation involves the use of a photosensitizing agent, a melanoma antigen (i.e. an antigenic molecule), for example a vaccine component, and irradiation with light of a wavelength effective to activate the photosensitizing agent. The invention also relates to said photosensitizing agent and melanoma antigen for use in such a method, and to cells produced by the method.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 13, 2021
    Assignee: PCI Biotech AS
    Inventors: Anders Høgset, Pål Johansen
  • Patent number: 10975159
    Abstract: Novel compounds which bind specifically to human CD160, including a light chain variable domain (VL), a chosen sequence defined by SEQ ID No: 14 or SEQ ID No: 13 and a heavy chain variable domain (VH), a sequence chosen from SEQ ID No: 11, SEQ ID No: 25, SEQ ID No: 26, SEQ ID No: 27, SEQ ID No: 28, SEQ ID No: 29 or SEQ ID No: 30, fragments thereof or derivatives thereof.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 13, 2021
    Assignee: ELSALYS BIOTECH
    Inventors: Alexandre Calcei, Hélène Haegel, Thierry Menguy, Caroline Rozan
  • Patent number: 10927435
    Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: February 23, 2021
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Xiaohong Huang, Martine Jasson, Vanessa Marks, Allen Radin
  • Patent number: 10906981
    Abstract: Provided herein are compositions, kits, methods and systems related to administering a structure that crosses the blood brain barrier (BBB) along with a monosaccharide, either simultaneously or consecutively. The structure may be, for example an antibody or fusion antibody that binds to an insulin receptor.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: February 2, 2021
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10835618
    Abstract: The present invention relates to an isolated specific binding member capable of binding sialyl-di-Lewisa, and associated treatments and pharmaceutical compositions for treatment of cancer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Inventors: Lindy Gillian Durrant, Mireille Vankemmelbeke, Silvana Tivadar, Tina Parsons, Richard McIntosh
  • Patent number: 10780182
    Abstract: A composition comprising at least one AAV vector formulated for central nervous system delivery is described. The composition comprises at least one expression cassette which contains sequences encoding an anti-neoplastic immunoglobulin construct for delivery to the brain operably linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The anti-neoplastic immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn). Also provided are methods of using these constructs in preparing pharmaceutical compositions and uses thereof in anti-neoplastic regimens, particularly for primary and/or metastatic cancers of the brain.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: September 22, 2020
    Inventors: James M. Wilson, William Thomas Rothwell, Christian Hinderer
  • Patent number: 10766962
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for FZD7, which preferably do not substantially interact with (bind to) other FZD family members, and methods of making said anti-FZD7 antibodies and binding fragments thereof. Another embodiment relates to antibodies and binding fragments comprising sequences of VH, VL and/or CDR polypeptides described herein. The invention also contemplates conjugates of anti-FZD7 antibodies and binding fragments. The invention further contemplates use of anti-FZD7 antibodies and binding fragments for tissue engineering. This invention also relates to a transgenic mouse expressing the epitope of anti-FZD7 antibodies and binding fragments thereof. Embodiments also pertain to use of anti-FZD7 antibodies and binding fragments (as well as the identified FZD7 epitope) for diagnosis, assessment, prevention and/or treatment of diseases and disorders associated with aberrant FZD7 expression, such as cancer.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Karl Willert, Dennis Carson
  • Patent number: 10718760
    Abstract: A method of determining the specific binding of ligand reversibly binding to a binding site in a sample using displacement competitive inhibition. The method comprising incubating the ligand (unlabeled) in the absence of a labeled ligand on a first tissue specimen, incubating the ligand (unlabeled) in the presence of a labeled ligand on a second tissue specimen, the first and the second tissue specimens being adjacent sections of specimen. MALDI imaging mass spectrometry is used to subsequently visualizing bound ligand localization, using in the first and second tissue specimen, respectively.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 21, 2020
    Assignee: TREAT4LIFE AB
    Inventors: Gyorgy Marko-Varga, Thomas Fehniger, Yutaka Sugihara
  • Patent number: 10717782
    Abstract: Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a Notch NRR (Negative Regulatory Region)-binding scFV fused to a transmembrane domain. Another aspect of the invention relates to drug-dependent synthetic proteins. Constructs and engineered cells comprising the synthetic proteins are additionally described herein.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: July 21, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: John T. Ngo
  • Patent number: 10696735
    Abstract: Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to a desired level.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: June 30, 2020
    Assignee: Outlook Therapeutics, Inc.
    Inventors: Chris Yonan, Christine Caroselli, Wiphusanee Dendamrongvit, Scott Gangloff
  • Patent number: 10689437
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 23, 2020
    Assignee: MedImmune, LLC
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Patent number: 10646544
    Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 12, 2020
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Makoto Kakitani, Kazuma Tomizuka
  • Patent number: 10611814
    Abstract: The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: April 7, 2020
    Assignee: GEMoaB Monoclonals GmbH
    Inventors: Michael Bachmann, Armin Ehninger
  • Patent number: 10590202
    Abstract: A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 17, 2020
    Assignee: BALIOPHARM AG
    Inventors: Andreas Herrmann, Ludger Grosse-Hovest
  • Patent number: 10544187
    Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 28, 2020
    Assignee: Xencor, inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • Patent number: 10517996
    Abstract: The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: December 31, 2019
    Assignee: Verigraft AB
    Inventors: Suchitra Sumitran-Holgersson, Michael Olausson
  • Patent number: 10500274
    Abstract: This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log10 to 2.5 log10 at about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 log10 at about nine days following administration of the CCR5 receptor antagonist.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: December 10, 2019
    Assignee: CytoDyn Inc.
    Inventors: William C. Olson, Paul J. Maddon, Daniel C. Pevear, Robert J. Israel, Jose D. Murga
  • Patent number: 10478491
    Abstract: As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an OX40 agonist and an Indoleamine 2,3-dioxygenase (IDO) inhibitor with the tumor antigen.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 19, 2019
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventor: Samir Khleif
  • Patent number: RE49192
    Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 30, 2022
    Assignee: INTERNATIONAL—DRUG—DEVELOPMENT BIOTECH
    Inventors: Claudine Vermot-Desroches, Boris Sebastien Vuillermoz